Patent Information
Recently, Yibo Biosciences submitted an invention patent for large-scale and customized dendritic cell exosomes.
The present invention combines the current advantages and defects of exosomes and cellular immunity to modify the exosomes of DC cellsSignificantly improve the anti-tumor immune effect of exosomes。The specific features are as follows:
1.overcomeMass production of DC exosomesThe biggest challenge is to ensure that there are enough exosomes for the first time.
2.UtilizationEngineered DC cell technology combined with genetic modification technology, so that DC exosomes carry and enrich the death molecules that induce apoptosis in tumor cells, so that they can specifically kill a variety of tumor cells, including lung cancer, liver cancer, melanoma, fibrosarcoma and cervical cancer. It is expected to be extended to other cancers including pancreatic cancer, prostate cancer, breast cancer, esophageal cancer, glioma, colorectal cancer, kidney cancer, and hematological tumors.
Figure: Yibo bioengineered DC exosomes significantly improved the killing effect of melanoma.
3.The DC exosomes involved in this patent are engineered DC cellsThe molecular composition is homogeneous, good stability. It carries DC-related active molecules that can activate immune cells and is a powerful immune adjuvant.
4.It only has a killing effect on tumor cells, but has no effect on normal cells.
The invention patent of Yibo Biosciences provides a preparation scheme for DC cell exosomes, which aims to provide an exosome of DC cells with anti-tumor activity, which is conducive to the expansion of application scenarios and is expected to benefit more cancer patients in the early stage of the disease.
Technical interpretation
To understand the role of this patent, it is necessary to understand two substances with anti-tumor properties:Exosomes and DC cells.
Exosomes are oneSecreted by cells, in the range of 60 - 150 nm in diameter, consists of a lipid bilayerVesicle structure
It's everywhere. From a macroscopic point of view, exosomes exist in all corners of the human body, such as blood, saliva, cerebrospinal fluid, milk, ascites, etcAt the microscopic level, important B cells, dendritic cells, T cells, and epidermal cells in the human body all release their own exosomes.
At the same time, different types of exosomes carry many important information about the human body, such as nucleic acids, proteins, and lipidsPlay the role of "communication soldiers" between cells, releasing signals that promote cell differentiation and proliferation, angiogenesis, stress response, immune response, etc.
Exosomes are also "both good and evil". Healthy cells, whose exosomes promote health;Conversely, tumor cell exosomes, such as tumor cells, can interfere with the normal operation of immune cells in the body.
In a nutshell:The quality of exosomes depends on the maternal cells.
In order to use exosomes that are beneficial in fighting tumors, it is undoubtedly necessary to find cells that can exert anti-tumor effects. Under this line of thinking, DC cells become the "chosen ones".
DC cell, short for dendritic cellIt is currently the most powerful antigen-presenting cell known to regulate in vivo。In terms of anti-tumor, it has a great application space.
In fact, DC, as a tumor product, has been widely used in research and clinical practice. As early as 2010, the US FDA has approved a DC vaccine for prostate cancer. Since then, a number of DC products have been launched around the world, with indications involving malignant melanoma, renal cell carcinoma, non-Hodgkin lymphoma, glioma, lung cancer, liver cancer, colorectal cancer, breast cancer, nasopharyngeal cancer and other diseases.
With the continuous advancement of global medicine, the anti-tumor effect of DC cells has gradually been recognized by the industry. But one of the big questions facing practitioners isThe inability to prepare DC cells on a large scale will make the production cost of this kind of ** high and the difficulty of marketization.
With its continuous cultivation in the field of DC cells, Yibo Biosciences has independently developed DC cellsAmplification, storage, R&D, and application in one's engineered DC cell technology platform.
After breaking the dilemma of large-scale preparation of DC cells, Yibo Biosciences continued to research on DC cell exosomes. It's one of a kindIt has good druggability and strong anti-tumor propertiesNanotechnology for drug delivery.
It has been found that DC cells release a large number of exosomes that bind a large number of tetratransmembrane proteins, such as CD9 and CD81, all known antigen-presenting molecules (major histocompatibility complex classes I and , CD1a, b, c, and D), and the costimulatory molecule CD86.
Figure: Exosome surface expression of ALIX and CD81 markers in Yibo bioengineered DC cells**.
The function of DC cellular exosomes is to activate antigen-specific T cells to promote cellular immune responses by combining the major histocompatibility complex class I and class molecules and other related molecules that carry antigens. Studies have shown that in mouse models,Antigen-loaded exosomes elicit strong antitumor activity.
DC exosomes have a variety of immunomodulatory functionsIt will be a very promising non-cellular nanovaccine in the future anti-tumor immunity**。And, due to the natural material transport properties of exosomes, the inherent long-term circulation ability and excellent biocompatibility,This makes DC exosomes have great potential as drug delivery vehicles, suitable for the delivery of various chemicals, proteins, nucleic acids and gene ** agents.
Large-scale preparation of exosomes of engineered DC cells with efficient anti-tumor effects is expected to play an important role in anti-tumor direction.